Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
EyePoint Pharmaceuticals Inc Market Cap
From what 0 stock analysts predict, the share price for EyePoint Pharmaceuticals Inc (EYPT) might increase by 349.21% in the next year. This is based on a 12-month average estimation for EYPT. Price targets go from $28 to $68. The majority of stock analysts believe EYPT is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
EyePoint Pharmaceuticals Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that EyePoint Pharmaceuticals Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of EYPT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Kambiz Yazdi Jefferies | Buy | $15 | Initiates | Aug 28, 2024 |
| Tessa Romero JP Morgan | Overweight | $29 | Maintains | Aug 13, 2024 |
| Daniil Gataulin Chardan Capital | Buy | $28 | Maintains | Jun 28, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $30 | Reiterates | Jun 27, 2024 |
| Jennifer Kim Cantor Fitzgerald | Overweight | Reiterates | Jun 20, 2024 | |
| Tessa Romero JP Morgan | Overweight | $32 | Maintains | Jun 4, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $30 | Maintains | May 13, 2024 |
Baird | Outperform | $38 | Maintains | May 8, 2024 |
| Daniil Gataulin Chardan Capital | Buy | $28 | Maintains | May 7, 2024 |
| Graig Suvannavejh Mizuho | Buy | $30 | Maintains | May 7, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $33 | Maintains | Mar 8, 2024 |
| Graig Suvannavejh Mizuho | Buy | $39 | Maintains | Feb 16, 2024 |
| Tessa Romero JP Morgan | Overweight | $35 | Initiates | Jan 22, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $33 | Maintains | Jan 16, 2024 |
| Zegbeh Jallah Capital One | Overweight | $44 | Initiates | Dec 11, 2023 |
| Graig Suvannavejh Mizuho | Buy | $30 | Maintains | Dec 7, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $35 | Maintains | Dec 5, 2023 |
| Graig Suvannavejh Mizuho | Buy | $20 | Initiates | Nov 2, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $25 | Maintains | Nov 2, 2023 |
| Jennifer Kim Cantor Fitzgerald | Overweight | $31 | Reiterates | Sep 14, 2023 |
When did it IPO
N/A
Staff Count
121
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Jay S. Duker M.D.
Market Cap
$486.5M
In 2023, EYPT generated $46.0M in revenue, which was a increase of 11.14% from the previous year. This can be seen as a signal that EYPT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
